Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)

South Korea flag South Korea · Delayed Price · Currency is KRW
10,410
-90 (-0.86%)
May 13, 2025, 3:30 PM KST
-50.43%
Market Cap 499.88B
Revenue (ttm) 15.05B
Net Income (ttm) -6.93B
Shares Out 48.02M
EPS (ttm) -174.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 100,900
Average Volume 168,495
Open 10,510
Previous Close 10,500
Day's Range 10,400 - 10,620
52-Week Range 9,320 - 22,700
Beta 1.06
RSI 38.65
Earnings Date May 14, 2025

About Hyundai Bioscience

Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2000
Employees 54
Stock Exchange KOSDAQ
Ticker Symbol 048410
Full Company Profile

Financial Performance

In 2024, Hyundai Bioscience's revenue was 15.05 billion, an increase of 58.73% compared to the previous year's 9.48 billion. Losses were -6.93 billion, -52.21% less than in 2023.

Financial Statements

News

There is no news available yet.